UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24, 2025
Artiva Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-42179 |
|
83-3614316 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
5505 Morehouse Drive, Suite 100
San Diego, California 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 267-4467
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value per share |
|
ARTV |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e) On June 24, 2025, Artiva Biotherapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2024 Equity Incentive Plan (the “2024 Plan” and the 2024 Plan, as amended, the “2024 Amended Plan”) to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 1,214,580 shares. The 2024 Amended Plan was previously approved, subject to stockholder approval, by the Company’s Board of Directors on April 16, 2025. A summary of the principal features of the 2024 Amended Plan are set forth under the heading “Proposal No. 3―Approval of Amendment to the Company’s 2024 Equity Incentive Plan” contained in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 29, 2025 (the “2025 Proxy Statement”). The summaries are qualified in their entirety by reference to the 2024 Amended Plan, filed as Exhibit 10.1 to this report.
|
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
(a) At the Annual Meeting, the Company’s stockholders voted on the proposals listed below, each of which was described in the 2025 Proxy Statement. As of April 25, 2025, the record date for the Annual Meeting, 24,363,119 shares of common stock were outstanding and entitled to vote at the Annual Meeting. The voting results are set forth below.
(b)
Proposal 1. Election of Class I Director
The Company’s stockholders elected the person listed below as a Class I director to serve a three-year term through the Company’s 2028 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal. The final voting results are as follows:
|
|
|
|
|
Votes For |
Votes Withheld |
Broker
Non-Votes |
Daniel Baker, Ph.D. |
18,913,133 |
22,995 |
1,838,803 |
Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:
|
|
|
|
Votes For |
Votes Against |
Abstentions |
Broker
Non-Votes |
20,772,359 |
300 |
2,272 |
— |
Proposal 3. To Approve an Amendment to the Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan
The Company’s stockholders approved an amendment to the 2024 Plan to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 1,214,580 shares. The final voting results are as follows:
|
|
|
|
Votes For |
Votes Against |
Abstentions |
Broker
Non-Votes |
16,350,669 |
2,583,159 |
2,300 |
1,838,803 |
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Artiva Biotherapeutics, Inc. |
|
|
By: |
|
/s/ Fred Aslan |
|
|
Fred Aslan, M.D. |
|
|
President and Chief Executive Officer |
Dated: June 25, 2025